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Decades of research and certainly more than 20,000 pa-
pers have been dedicated to the health benefits of omega-3 
long-chain polyunsaturated fatty acids (n-3 LC-PUFAs). 
We have learned that n-3 LC-PUFAs modulate multiple 
molecular processes and exert pleiotropic beneficial ef-
fects that, depending on the pathophysiological context, 
may range from anti-inflammation and triglyceride-lowering 
to cardioprotection and anti-arrhythmia, or even im-
proved cognitive function (1, 2). However, a challenging 
question remains about how molecular events translate 
into physiological responses and finally to desired health 
benefits. Currently, there is also the issue that a series of 
recent clinical trials showed insufficient evidence for the 
therapeutic efficacy of n-3 LC-PUFA supplements. Taking 
the otherwise overwhelming epidemiological, preclinical, 
and mechanistic evidence for granted, we are forced to 
critically analyze what we know about the principles, op-
portunities, and limitations of n-3 LC-PUFA actions. This 
is an ongoing process that will have consequences for de-
signing appropriate future clinical trials, stimulating re-
search on important open questions, and improving our 
understanding of the therapeutic potential of n-3 LC-PUFA 
supplements.
In this commentary, only two general topics will be dis-
cussed; namely, the features of n-3 LC-PUFA supplements 
that differentiate them from “normal drugs” and the role 
of n-3 LC-PUFAs as precursors of novel lipid mediators 
with highly potent cardiovascular actions. This is to pro-
vide some background for the specific “EPA and/or DHA” 
question, and how this question has been addressed by the 
recent study of McManus et al. (3) published in this issue 
of the Journal of Lipid Research that deals with the differen-
tial effects of EPA vs. DHA on postprandial vascular func-
tion and the plasma oxylipin profile in men.
n-3 LC-PUFA supplements. The n-3 LC-PUFA supplements 
typically used in clinical trials and already prescribed for 
triglyceride-lowering or cardiac protection contain EPA 
(eicosapentaenoic acid; C20:5 n-3) and DHA (docosa-
hexaenoic acid; C22:6 n-3), in a ratio of approximately 3:2. 
Whereas drugs can be given or not given to a patient, n-3 
LC-PUFAs are essential constituents of the body. At least 
some basic, but frequently suboptimal, supply is secured 
via the intake of vegetables providing the respective C18 
precursor (a-linolenic acid; C18:3 n-3) or directly through 
EPA- and DHA- containing marine food components. Sim-
ilar considerations apply to arachidonic acid (AA; C20:4 
n-6), the physiologically most important n-6 LC-PUFA. 
Meat and dairy products deliver AA directly. Moreover, 
the respective C18 precursor (linoleic acid, LA; C18:2 n-6) 
is supplied in overly large amounts in the vegetable oils 
and cereal products. Beyond the nutrition that determines 
the n-3/n-6 balance, there are gene-diet interactions, hor-
monal and epigenetic regulation, as well as disease state-
related factors that modulate an individual’s capacity to 
synthesize n-3 and n-6 LC-PUFAs from their C18 precur-
sors. Intriguingly, functional genetic polymorphisms in 
this pathway were probably subject to “positive selection” 
during human evolution in adaptation to specific nutri-
tional environments (4). The current distribution of the 
corresponding genetic variants is different in different 
populations, and excitingly, also when comparing, for ex-
ample, coronary artery disease patients with healthy con-
trols (5). In consequence, all these factors contribute to 
the fact that patients enrolled to receive EPA/DHA- 
supplementation will exhibit individually different baseline 
levels of n-3 vs. n-6 LC-PUFAs. Similarly important, these 
factors might also modulate the effect size of EPA/DHA-
supplementation with regard to the achieved changes in 
endogenous fatty acid profiles. Furthermore, the time 
course of n-3 LC-PUFA induced changes merits indication-
specific attention. Unlike the acute postprandial increases 
of plasma EPA- and DHA-levels to be discussed below, the 
incorporation and wash-out kinetics of EPA and DHA pro-
ceeds on a time scale ranging from days (plasma phospho-
lipids in fasting state) to weeks (red blood cells reflecting 
also cardiac tissue) to months in adipose tissues (6). Un-
fortunately, data on intervention-induced changes in fatty 
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acid profiles exist for some but not all clinical trials, in-
cluding the GISSI-P study (7) that largely established our 
belief in the benefits of n-3 LC-PUFAs. Without recogniz-
ing and overcoming these obvious confounders, it will re-
main difficult to define the target EPA/DHA-levels and 
treatment times for desired therapeutic effects and also to 
understand why there are such large discrepancies in the 
outcomes of different human studies with n-3 LC-PUFAs. 
Moreover, we need to learn more about the genetic poly-
morphisms in PUFA metabolism that potentially predis-
pose to cardiovascular disease in a diet-dependent manner 
and may also modulate individual responses to n-3LC-
PUFA supplementation.
n-3 LC-PUFAs as precursors of novel lipid mediators. The other 
principle to be considered stems from experimental evi-
dence indicating that many of the beneficial cardiovascular 
effects attributed to n-3 LC-PUFAs are associated with their 
precursor roles in lipid mediator formation. This notion is 
currently facing a revival and is still expanded in ongoing 
experiments. Classical work suggested that EPA competes 
with AA for the conversion by cyclooxygenases (COXs) and 
lipoxygenases (LOXs), resulting in the formation of less 
potent pro-inflammatory eicosanoids (8, 9). This concept 
has been further refined for the COX and LOX pathways 
(10, 11) and extended by identification of EPA- and DHA-
derived lipid mediators with powerful biological activities. 
These most recently recognized lipid mediators include 
the “specialized pro-resolving metabolites” (SPMs: re-
solvins, protectins, and maresins) (12) and the “omega-3 
epoxyeicosanoids” generated by cytochrome P450 (CYP) 
enzymes (13). In line with the substrate- and regioselectiv-
ity of the CYP enzymes, 17,18-epoxyeicosatetraenoic acid 
(17,18-EEQ alias 17,18-EpETE) becomes the predominant 
endogenous epoxyeicosanoid after EPA/DHA supplemen-
tation both in rodents and man (14). Less is known about 
the diet-dependent formation of SPMs because analytical 
methods have been reported by only a few laboratories 
(15). 17,18-EEQ appears to function as a highly potent 
mediator of cardioprotective and antiarrhythmic effects of 
EPA (13). As demonstrated in in vitro and animal stud-
ies, 17,18-EEQ also displays vasodilatory, anti-inflamma-
tory, and anti-allergic properties that contribute to the 
beneficial effects of n-3 LC-PUFAs in diverse disease states 
ranging from bronchial disorders (16), fatty liver disease 
(17), and intraocular neovascularization (18) to allergic 
intestinal inflammation (19). The DHA-derived 19,20- 
epoxydocosapentaenoic acid (19,20-EDP alias 19,20-Ep-
DPE) shares several of these properties but has attracted 
the most attention due to its capacity to inhibit tumor an-
giogenesis and proliferation (20). The much longer known 
AA-derived omega-6 epoxyeicosanoids have in part similar 
or less potent and even opposite effects compared with 
their omega-3 counterparts (21, 22). A limitation for bio-
logical activities of the CYP epoxygenase products is their 
rapid metabolization to less active diols by soluble epoxide 
hydrolase (sEH), an enzyme known to be increased in sev-
eral disease states (23). Based on these preclinical studies, 
much recent research, including the study presented by 
McManus et al., is aimed at understanding the relevance of 
the CYP epoxygenase/sEH-pathway in humans. LC-MS/
MS-based profiling of both the classical and novel LC-PUFA-
derived lipid mediators has been developed in several labo-
ratories. This lipid mediator profiling may yield biomarkers 
that are closely linked to the cardiovascular actions of n-3 
and n-6 LC-PUFAs. It also provides novel opportunities for 
recognizing genetic as well as disease state- and comedica-
tion-related factors potentially limiting the response to 
EPA/DHA-supplementation, as these could modulate and 
reduce the formation of specific EPA/DHA-derived bioac-
tive lipid mediators.
The “EPA and/or DHA” question. One of the apparently sim-
ple but truly difficult questions to answer in this research 
field concerns differences in actions between EPA and 
DHA. Summarizing all the mechanism-, cell-type-, risk 
marker-, and indication-specific findings, the best general 
answer currently possible seems to be the following: there 
are shared and differential as well as complementary and 
synergistic effects of EPA and DHA (24, 25). This question 
is also related to current attempts of tailoring the EPA:DHA-
ratio to the treatment needs of specific indications. Hope-
fully, we will see soon whether or not these attempts will be 
successful to produce reproducible clinical effects and thus 
evidence-based recommendations.
In the current issue of the Journal of Lipid Research, 
McManus et al. make a rather good case for addressing the 
“EPA and/or DHA question” in a specific physiological 
condition; namely, the postprandial state and its effect on 
vascular function and arterial stiffness. Arterial stiffness 
was characterized primarily by measuring the “Pulse Wave 
Velocity and Augmentation Index” (AIx). The interven-
tions included control as well as EPA- and DHA-rich test 
meals. The resulting changes in vascular function and 
plasma fatty acid profiles were analyzed by comparing 
the corresponding values before and 4 h after giving the 
test meals. Moreover, the authors quantified several oxy-
lipins, in particular, the omega-3 epoxyeicosanoids dis-
cussed above, as well as nitrite and hydrogen sulfide, as 
mediators and biomarkers of the mechanisms potentially 
contributing to the EPA/DHA-induced-changes in vascu-
lar function.
Briefly summarized, the results show that DHA im-
proved postprandial vascular function (reduced AIx) with 
an effect size that would translate into a meaningful reduc-
tion in cardiovascular disease (CVD) risk. A strong trend 
was also evident following the EPA intervention. Moreover, 
oxylipin-profiling indicated that postprandial changes in 
the formation of omega-3 epoxyeicosanoids may play a 
mechanistic role in mediating the observed beneficial ef-
fect on vascular function.
The authors explain the rationale of selecting the post-
prandial state by referring to the fact that the postprandial 
state typically covers up to 18 h per day in adults following 
Westernized dietary patterns. Accordingly, the postpran-
dial phenotype appears more relevant than the fasting 
one for evaluating CVD risk markers, such as vascular dys-
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postprandial state is associated with increases in lipemia 
and glycemia as well as inflammatory stress, providing a 
challenge for the maintenance of vascular function. The 
authors, recruited volunteers possessing a moderately in-
creased CVD risk, based on blood lipids, blood pressure, 
and waist circumference. Taken together, the selection of 
the postprandial state as well as of participants at risk can 
be considered to increase the likelihood of success, since 
the benefits of EPA/DHA-supplementation are frequently 
only revealed under challenging conditions. However, 
and potentially influencing the effect size, baseline fatty 
acid profiles were not considered when selecting the 
participants.
The participants received high-fat test meals providing 
4.16 g EPA or DHA or control oil. The fatty acid composi-
tion of the test meals showed that the control meal, con-
taining a palm oil/soybean mixture, was indeed free of 
any LC-PUFAs. The EPA:DHA-ratios were about 5:1 in the 
EPA-rich oil (ERO) and 1:6 in DHA-rich oil (DRO). 
Whereas the control meal did not change the total plasma 
concentrations of n-3 LC-PUFAs, the ERO meal specifi-
cally increased the EPA levels by about 250% and DHA was 
increased by almost 200% after the DRO meal. Test meals 
containing other intentionally adjusted EPA+DHA mix-
tures were not included. This is a shortcoming of this study 
when asking for potentially additive or synergistic effects 
of EPA and DHA.
In line with previous studies (26, 27), but nonetheless 
still impressive, the period of only 4 h was sufficient to gen-
erate significant increases in the circulating levels of EPA- 
and DHA-derived oxylipins. Although some blood cells, 
like monocytes/macrophages (28), express CYP-enzymes, 
major sites of CYP-epoxygenase activities are the endothe-
lium, liver, and other organs. Moreover, CYP enzymes 
need their substrates in a free form, making the release of 
EPA and DHA, either from lipoproteins in the circulation 
or later in the cells and tissues, an essential precondition 
for the enzymatic production of omega-3 epoxyeico-
sanoids. Without further data, we can only speculate about 
the postprandial transport and lipase-dependent processes 
that make EPA and DHA so quickly accessible to the CYP 
enzymes in blood cells, the endothelium, or other tissues. 
Once produced, the CYP-eicosanoids themselves can be 
esterified into phospholipids. At least in the fasting state, 
the majority of these metabolites circulate esterified pri-
marily with lipoproteins. From this reservoir, the CYP- 
eicosanoids can be released by lipoprotein lipase, making 
direct interactions with the vasculature possible (29). The 
other and more established pathway of CYP epoxyeicosanoid-
mediated vascular actions consists in their production in 
the endothelium followed by paracrine relaxing effects on 
vascular smooth muscle cells (30). The present study ex-
clusively analyzed the nonesterified circulating oxylipins, 
leaving open whether or not similarly rapid postprandial 
changes also occurred with the esterified metabolites.
Furthermore, the observed changes in oxylipin profiles 
merit some detailed comments. The EPA-derived 17,18-
EEQ and its sEH-generated diol (17,18-DiHETE) became 
the predominant metabolites, surprisingly, not only after 
giving the ERO but also the DRO test meal. In contrast, 
the metabolism of DHA via the same CYP epoxygenase/
sEH-pathway was detectable only by an increase of the diol 
metabolite (19,20-DiHDPA) that occurred specifically in 
the DRO group. Taking the sum of epoxy and diol me-
tabolites, the EPA-derived metabolites exceeded the ones 
from DHA by a factor of 15 postprandial to the EPA-rich 
meal and still 8-fold after the DHA-rich meal. Presumably, 
DRO intervention provided in addition to DHA also suffi-
cient amounts of EPA (supposedly as contaminant or ret-
roconversion product of DHA) for the CYP epoxygenases 
that generally prefer EPA over DHA (14).
As discussed by the authors, this state-of-affairs suggests 
that, following DHA intervention, both DHA and EPA and 
their CYP-generated oxylipins may act in a complementary 
and additive fashion to mediate the impact on vascular func-
tion. Searching for the underlying mechanisms, it might be 
worth considering that, beyond exerting direct vascular ef-
fects, CYP epoxygenase-generated metabolites also have the 
capacity to limit monocyte activation (28), a process that may 
also occur in the postprandial state and in turn contribute to 
the development of vascular dysfunction.
Finally, it also should be noted that many members of 
the huge oxylipin family were below the detection limit or 
not accessible through the LC-MS/MS method used by 
the authors. Beyond the CYP-derived metabolites dis-
cussed in detail above, the oxylipin profile presented is 
rather incomplete, precluding notions about the potential 
involvement of SPMs and other lipid mediators. It also 
would have been interesting to learn to what extent EPA 
and DHA were able to outcompete the postprandial for-
mation of CYP epoxygenase products derived from n-6 
PUFAs such as AA and LA. Considering these open ques-
tions and also the promises of CYP eicosanoid and SPM 
lipid mediator profiling discussed in the background part 
of this commentary, the whole research field would bene-
fit greatly from the analytical experts in different laborato-
ries initiating inter-laboratory tests and joint efforts to 
improve and standardize the required analytical methods 
ranging from sample preparation to LC-MS/MS-based 
quantification.
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